Development of 3D PVA scaffolds for cardiac tissue engineering and cell screening applications.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
30 Jan 2019
30 Jan 2019
Historique:
received:
03
10
2018
accepted:
05
01
2019
entrez:
6
5
2022
pubmed:
14
2
2019
medline:
14
2
2019
Statut:
epublish
Résumé
The aim of this study was the design of a 3D scaffold composed of poly(vinyl) alcohol (PVA) for cardiac tissue engineering (CTE) applications. The PVA scaffold was fabricated using a combination of gas foaming and freeze-drying processes that did not need any cross-linking agents. We obtained a biocompatible porous matrix with excellent mechanical properties. We measured the stress-strain curves of the PVA scaffolds and we showed that the elastic behavior is similar to that of the extracellular matrix of muscles. The SEM observations revealed that the scaffolds possess micro pores having diameters ranging from 10 μm to 370 μm that fit to the dimensions of the cells. A further purpose of this study was to test scaffolds ability to support human induced pluripotent stem cells growth and differentiation into cardiomyocytes. As the proliferation tests show, the number of live stem cells on the scaffold after 12 days was increased with respect to the initial number of cells, revealing the cytocompatibility of the substrate. In addition, the differentiated cells on the PVA scaffolds expressed anti-troponin T, a marker specific of the cardiac sarcomere. We demonstrated the ability of the cardiomyocytes to pulse within the scaffolds. In conclusion, the developed scaffold show the potential to be used as a biomaterial for CTE applications.
Identifiants
pubmed: 35520194
doi: 10.1039/c8ra08187e
pii: c8ra08187e
pmc: PMC9060459
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4246-4257Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Acta Biomater. 2017 Apr 1;52:81-91
pubmed: 27940161
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Biomaterials. 2013 Oct;34(30):7269-80
pubmed: 23810254
Nat Protoc. 2016 Oct;11(10):1775-81
pubmed: 27583639
Ann Cardiothorac Surg. 2018 Jan;7(1):56-66
pubmed: 29492383
J Tissue Eng Regen Med. 2017 May;11(5):1658-1674
pubmed: 26777594
Sci Rep. 2014 Oct 22;4:6716
pubmed: 25336194
Circ Res. 2014 Jan 17;114(2):354-67
pubmed: 24436431
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15211-6
pubmed: 20696917
Drugs. 2018 Apr;78(5):567-576
pubmed: 29536372
J Cardiovasc Transl Res. 2017 Apr;10(2):180-193
pubmed: 28265882
Nanoscale. 2017 Jun 1;9(21):7081-7093
pubmed: 28513711
Colloids Surf B Biointerfaces. 2013 Jul 1;107:137-45
pubmed: 23475061
Science. 2010 Jul 30;329(5991):538-41
pubmed: 20576850
Future Cardiol. 2007 Jul;3(4):425-34
pubmed: 19804233
Nat Methods. 2011 Apr;8(4):315-7
pubmed: 21378979
Biomaterials. 2004 Mar;25(6):1077-86
pubmed: 14615173
Small. 2013 Feb 11;9(3):402-12
pubmed: 23027505
Organogenesis. 2015;11(2):47-57
pubmed: 26252820
J Biomed Mater Res. 2002 Aug;61(2):212-7
pubmed: 12007201
Science. 2009 Apr 3;324(5923):98-102
pubmed: 19342590
Stem Cells. 2013 May;31(5):829-37
pubmed: 23355363
Cardiovasc Drugs Ther. 2018 Apr;32(2):223-232
pubmed: 29633048
Nanomicro Lett. 2017;9(1):1
pubmed: 30460298
Cell Death Dis. 2018 Jan 5;9(1):6
pubmed: 29305588
Cell Biol Toxicol. 2017 Apr;33(2):99-112
pubmed: 27900567
Sci Transl Med. 2016 Jun 8;8(342):342ps13
pubmed: 27280684
Langmuir. 2013 Jan 8;29(1):82-91
pubmed: 23214919
Nanomedicine (Lond). 2014 May;9(6):859-75
pubmed: 24981651
Tissue Eng Part A. 2016 Aug;22(15-16):1016-25
pubmed: 27392582
J Mater Chem B. 2016 Jul 7;4(25):4410-4419
pubmed: 32263423
J Tissue Eng Regen Med. 2014 Feb;8(2):164-8
pubmed: 22549901
Cytotechnology. 2016 May;68(3):355-69
pubmed: 26091616
Adv Drug Deliv Rev. 2016 Jan 15;96:203-13
pubmed: 26428618
J Mech Behav Biomed Mater. 2017 Jan;65:657-664
pubmed: 27741496